The abstract is read at the publisher; the summary is JClub's.
High GITR RNA expression is linked to better restricted mean survival time in 489 patients with advanced/metastatic cancers, including 272 not treated with immunotherapy.
- Why it matters: The relationship between GITR and its ligand GITR-L expression and patient outcomes is unclear, limiting how these immune markers might be used for prognosis and immunotherapy response.
- What they did: The study analyzed transcript expression patterns of GITR and GITR-L in 489 advanced/metastatic cancer patients, using restricted mean survival time because subgroup survival curves did not show proportional hazards. Multivariate models adjusted for RNA expression of other immune modulators.
- The result: High GITR plus low/moderate GITR-L RNA expression is associated with longer overall survival in the 217 immunotherapy-treated patients, and no GITR-correlated progression-free survival associations were seen there.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.